Narazaciclib is under clinical development by Onconova Therapeutics and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase II drugs for Endometrial Cancer have a 22% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Narazaciclib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ON-123300 is under development for the treatment of solid tumors and hematological tumors including glioblastoma multiforme, colorectal cancer, multiple myeloma, mantle cell lymphoma, hepatocellular carcinoma, recurrent metastatic low-grade endometrioid endometrial cancer (LGEEC) and HER-2 negative metastatic breast cancer including triple-negative breast cancer. It is a small molecule administered orally. It acts by targeting cyclin-dependent kinase 4 (CDK4), cyclin-dependent kinase 6 (CDK6) enzyme and ARK5.
Onconova Therapeutics overview
Onconova Therapeutics (Onconova) is a biopharmaceutical company that discovers and develops small molecule drug candidates for the treatment of cancer. The company’s drug candidates include rigosertib and ON123300. It develops drug candidates that target cancer and protect healthy cells based on its proprietary chemistry platform and cell-based differential screening. Onconova’s rigosertib is targeted at meeting the medical needs of patients with myelodysplastic syndromes. The company’s recilisib is used to treat the effects of acute radiation syndromes such as cytopenia. It partnered with biopharmaceutical companies and medical organizations in the US. Onconova is headquartered in Newtown, Pennsylvania, the US.
For a complete picture of Narazaciclib’s drug-specific PTSR and LoA scores, buy the report here.